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Allogeneic stem cell transplantation (alloSCT) can be a curative treatment for hematolog-
ical malignancies. Unfortunately, the desired anti-tumor or graft-versus-leukemia (GvL) 
effect is often accompanied with undesired side effects against healthy tissues known 
as graft-versus-host disease (GvHD). After HLA-matched alloSCT, GvL and GvHD are 
both mediated by donor-derived T-cells recognizing polymorphic peptides presented 
by HLA surface molecules on patient cells. These polymorphic peptides or minor histo-
compatibility antigens (MiHA) are produced by genetic differences between patient and 
donor. Since polymorphic peptides may be useful targets to manipulate the balance 
between GvL and GvHD, the dominant repertoire of MiHA needs to be discovered. In 
this review, the diversity of autosomal MiHA characterized thus far as well as the various 
molecular mechanisms by which genetic variants create immune targets and the role of 
cryptic transcripts and proteins as antigen sources are described. The tissue distribution 
of MiHA as important factor in GvL and GvHD is considered as well as possibilities how 
hematopoietic MiHA can be used for immunotherapy to augment GvL after alloSCT. 
Although more MiHA are still needed for comprehensive understanding of the biology of 
GvL and GvHD and manipulation by immunotherapy, this review shows insight into the 
composition and kinetics of in vivo immune responses with respect to specificity, diver-
sity, and frequency of specific T-cells and surface expression of HLA–peptide complexes 
and other (accessory) molecules on the target cell. A complex interplay between these 
factors and their environment ultimately determines the spectrum of clinical manifesta-
tions caused by immune responses after alloSCT.
Keywords: allogeneic stem cell transplantation, hematological malignancy, graft-versus-leukemia reactivity, 
graft-versus-host disease, donor lymphocyte infusion, T-lymphocytes, minor histocompatibility antigens, 
immunotherapy
Abbreviations: alloSCT, allogeneic stem cell transplantation; DLI, donor lymphocyte infusion; DRiP, defective ribosomal 
product; GvHD, graft-versus-host disease; GvL, graft-versus-leukemia reactivity; MiHA, minor histocompatibility antigen; 
SNP, single nucleotide polymorphism; WGAs, whole genome association scanning.
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ALLOGeneiC STeM CeLL 
TRAnSPLAnTATiOn
Allogeneic stem cell transplantation (alloSCT) can be a cura-
tive treatment for hematological malignancies. In alloSCT, the 
immune system from a healthy donor is transplanted into the 
patient to induce an effective response against the leukemic cells 
(1, 2). Unfortunately, desired anti-tumor or graft-versus-leukemia 
(GvL) reactivity is often accompanied with graft-versus-host 
disease (GvHD) affecting predominantly skin, gut, liver, and 
lungs (3–6). To reduce GvHD, donor T-cells can be (partially) 
depleted from the stem cell graft (7–9). T-cell depletion decreases 
the incidence and severity of GvHD, but increases the risk of 
leukemia relapse and opportunistic infections. Once toxicity of 
the conditioning has subsided, donor T-cells can be administered 
after alloSCT as donor lymphocyte infusions (DLI) to reinstall 
beneficial GvL (10, 11). Although DLI can induce long-lasting 
clinical remissions, GvHD remains a major cause of morbidity 
and mortality. Since DLI is applied to patients who do not receive 
(or only limited) immunosuppression, postponed DLI after 
alloSCT creates an ideal platform to study specificity, magnitude, 
and duration of GvL and GvHD.
MinOR HiSTOCOMPATiBiLiTY AnTiGenS
To minimize GvHD, patients with hematological malignancies 
are preferably transplanted with HLA-matched donors (12, 13). 
After HLA-matched alloSCT, donor-derived T-cells can mediate 
GvL and GvHD by recognizing polymorphic peptides presented 
on patient cells by shared HLA molecules. In the classical dogma, 
intracellular proteins are degraded in the cytosol by the protea-
some and peptides are presented by HLA class I to CD8 T-cells 
(14, 15). HLA class II molecules present peptides derived from 
intra- and extracellular proteins to CD4 T-cells (14, 16). In the 
autologous situation, peptides from normal cellular proteins can-
not be recognized by the immune system due to negative selection 
and deletion of self-specific T-cells in the thymus (17). After HLA-
matched alloSCT, however, donor T-cells recognize polymorphic 
peptides presented on patient cells by shared HLA as “non-self.” 
These polymorphic peptides or so-called minor histocompat-
ibility antigens (MiHA) can be encoded by the male-specific 
Y-chromosome (H-Y antigens) or other chromosomes (autosomal 
MiHA) and are produced by genetic differences between patient 
and donor (18–21). This review is focused on discovery strategies 
and molecular mechanisms behind autosomal MiHA.
T-CeLL iSOLATiOn
Minor histocompatibility antigen-specific T-cells can be directly 
isolated from in vivo immune responses after alloSCT or generated 
in vitro by stimulating antigen-experienced or naive donor T-cells 
(22, 23). T-cells have been isolated from in vivo immune responses 
by their capacity to produce IFN-γ upon in vitro stimulation with 
patient hematopoietic cells (24, 25). A disadvantage is that not 
all specific T-cells produce IFN-γ during 5–24 h of incubation, 
resulting in low T-cell isolation efficiencies. HLA-DR is a marker 
that has successfully been used to isolate in vivo activated T-cells 
(26, 27). Since HLA-DR is expressed on activated T-cells for a 
prolonged time, its expression does not require in vitro stimula-
tion and enables analysis of the in vivo immune response without 
introducing a bias. CD137 is another marker that allows direct 
isolation of antigen-experienced T-cells (28, 29). This marker is 
specific for T-cells that are recently activated and requires in vitro 
stimulation for re-expression on the cell surface.
DiSCOveRY STRATeGieS
To develop strategies that allow manipulation of GvL and 
GvHD, the dominant repertoire of autosomal MiHA needs to 
be discovered. HA-1 and HA-2 are the first MiHA that have been 
identified as T-cell targets in a patient with GvHD (Table  1). 
The antigens have been characterized as peptides eluted from 
HLA surface molecules that are recognized by specific T-cells 
by mass spectrometry. Other MiHA characterized by this 
approach are HA-8, HA-3, PANE1, and LB-ADIR-1F (Table 1). 
cDNA library screening in which pools of plasmids are tested 
for T-cell recognition is another technique that has been used 
for discovery of HB-1H, UGT2B17/A29, UGT2B17/B44, ACC-
4, ACC-5, ACC-6, SP110, LB-ECGF-1H, C19ORF48, TRIM22, 
and LB-TRIP10-1EPC (Table  1). In addition, five HLA class 
II-restricted MiHA encoded by PI4K2B, PTK2B, LY75, MR1, 
and MTHFD1 have been characterized by screening a library in 
which recombinant bacteria are screened for T-cell recognition 
(Table 1).
Due to advanced array techniques to measure single nucleotide 
polymorphisms (SNPs), whole genome association scanning 
(WGAs) became available as efficient method for MiHA discovery 
(39, 43). In this approach, a panel of test cells with known SNP 
genotypes is used to measure T-cell recognition. T-cell recognition 
is subsequently investigated for association with individual SNPs 
to identify the genomic region that encodes the MiHA. Before SNP 
arrays became commercially available, WGAs was performed with 
low-resolution genetic markers, leading to identification of large 
genomic regions of which all genes needed to be investigated for 
encoding the antigen. MiHA characterized by WGAs with low-
resolution markers are ACC-1Y, ACC-2, LRH-1, and HEATR1 
(Table  1). When high-resolution SNP data are used, WGAs 
enables direct identification of the MiHA-producing SNP or iden-
tification of small genomic regions with SNP(s) that are in linkage 
disequilibrium with the MiHA-producing SNP. MiHA identified 
with high- resolution SNP data are ACC-1C, SLC1A5, UGT2B17/
A2, DPH1, P2RX7, LB-PRCP-1D, SSR1-1S, LB-WNK1-1I, 
LB-EBI3-1I, LB-BCAT2-1R, LB-ARHGDIB-1R, LB-PDCD11-1F, 
LB-APOBEC3B-1K, LB-GEMIN4-1V, LB-ERAP1-1R, ZAPHIR, 
LB-SON-1R, LB-NUP133-1R,  LB-SWAP70-1Q, UTA2-1, and 
LB-FUCA2-1V (Table 1). WGAs with high-resolution SNPs also 
led to discovery of HLA class II-restricted MiHA encoded by 
CD19, SLC19A1, and ZDHHC12 (Table 1). Nowadays, data for 
all SNPs as present in the human genome are available in the 1000 
Genomes Project and the value of this dataset has recently been 
illustrated by discovery of UTDP4-1 (Table 1).
TABLe 1 | HLA class i- and ii-restricted autosomal minor histocompatibility antigens.
HLA-i MiHA MiHA/Ava Gene variant rs number Location Transcriptb Proteinb HLA Reference
HA-3 V[T/M]EPGTAQY AKAP13 SNP rs2061821 Exon Normal Normal A*01:01 (30)
HA-2 YIGEVLVS[v/M] MYO1G SNP rs61739531 Exon Normal Normal A*02:01 (31)
HA-1/A2 VL[H/R]DDLLEA HMHA1 SNP rs1801284 Exon Normal Normal A*02:01 (32)
HA-8 [R/P]TLDKVLEV KIAA0020 SNP rs2173904 Exon Normal Normal A*02:01 (33)
LB-ADIR-1F SVAPALAL[F/S]PA TOR3A SNP rs2296377 Exon Normal Alternative A*02:01 (34)
C19ORF48 CIPPD[S/T]LLFPA C19ORF48 SNP rs3745526 Exon Normal Alternative A*02:01 (35)
TRIM22 MAVPPC[C/R]IGV TRIM22 SNP rs187416296 Exon Normal Normal A*02:01 (22)
LB-PRCP-1D FMWDVAE[D/E]LKA PRCP SNP rs2298668 Exon Normal Normal A*02:01 (27)
LB-SSR1-1S [S/L]LAVAQDLT SSR1 SNP rs10004 Exon Normal Normal A*02:01 (27)
LB-WNK1-1I RTLSPE[i/M]ITV WNK1 SNP rs12828016 Exon Normal Normal A*02:01 (27)
T4A GLYTYWSAG[A/E] TRIM42 SNP rs9876490 Exon Normal Normal A*02:01 (36)
UTA2-1 QL[L/P]NSVLTL KIAA1551 SNP rs2166807 Exon Normal Normal A*02:01 (37)
LB-HIVEP1-1S SLPKH[S/N]VTI HIVEP1 SNP rs2228220 Exon Normal Normal A*02:01 (38)
LB-NISCH-1A ALAPAP[A/V]EV NISCH SNP rs887515 Exon Normal Normal A*02:01 (38)
UGT2B17/A2 CVATMIFMI UGT2B1 Gene deletion Polymorphic Polymorphic A*02:06 (39)
PANE1 RVWDLPGVLK CENPM SNP rs5758511 Exon Alternative Polymorphic A*03:01 (40)
SP110 SLP[R/G]GTSTPK SP110 SNP rs1365776 Exon Normal Normal A*03:01 (41)
ACC-1Y DYLQ[Y/C]VLQI BCL2A1 SNP rs1138357 Exon Normal Normal A*24:02 (42)
ACC-1C DYLQ[Y/C]VLQI BCL2A1 SNP rs1138357 Exon Normal Normal A*24:02 (43)
UGT2B17/A29 AELLNIPFLY UGT2B17 Gene deletion Polymorphic Polymorphic A*29:02 (44)
P2RX7 WFHHC[H/R]PKY P2RX7 SNP rs7958311 Exon Normal Normal A*29:02 (45)
ACC-4 ATLPLLCA[R/G] CTSH SNP rs2289702 Exon Normal Normal A*31:01 (46)
ACC-5 WATLPLLCA[R/G] CTSH SNP rs2289702 Exon Normal Normal A*33:03 (46)
LRH-1 TPNQRQNVC P2X5 INDEL rs3215407 Exon Normal Polymorphic B*07:02 (47)
LB-ECGF-1H RP[H/R]AIRRPLAL TYMP SNP rs112723255 Exon Normal Alternative B*07:02 (48)
LB-APOBEC3B-
1K
[K/E]PQYHAEMCF APOBEC3B SNP rs2076109 Exon Normal Normal B*07:02 (27)
LB-ARHGDIB-1R LPRACW[R/P]EA ARHGDIB SNP rs4703 Exon Normal Alternative B*07:02 (27)
LB-BCAT2-1R QP[R/T]RALLFVIL BCAT2 SNP rs11548193 Exon Normal Normal B*07:02 (27)
LB-EBI3-1I RPRARYY[i/V]QV EBI3 SNP rs4740 Exon Normal Normal B*07:02 (27)
LB-ERAP1-1R HPRQEQIALLA ERAP1 SNP rs26653 Exon Normal Normal B*07:02 (27)
LB-GEMIN4-1V FPALRFVE[v/E] GEMIN4 SNP rs4968104 Exon Normal Normal B*07:02 (27)
LB-PDCD11-1F GPDSSKT[F/L]LCL PDCD11 SNP rs2986014 Exon Normal Normal B*07:02 (27)
ZAPHIR IPRDSWWVEL ZNF419 SNP rs2074071 Exon Polymorphic Polymorphic B*07:02 (49)
LB-FUCA2-1V RLRQ[v/M]GSWL FUCA2 SNP rs3762002 Exon Normal Normal B*07:02 (50)
LB-TEP1-1S APDGAKVA[S/P]L TEP1 SNP rs1760904 Exon Normal Normal B*07:02 (51)
HEATR1 ISKERA[e/G]AL HEATR1 SNP rs2275687 Exon Normal Normal B*08:01 (23)
HA-1/B60 KECVL[H/R]DDL HMHA1 SNP rs1801284 Exon Normal Normal B*40:01 (52)
LB-NUP133-1R SEDLILC[R/Q]L NUP133 SNP rs1065674 Exon Normal Normal B*40:01 (53)
LB-SON-1R SETKQ[R/C]TVL SON SNP rs13047599 Exon Normal Normal B*40:01 (53)
LB-SWAP70-1Q MEQLE[Q/E]LEL SWAP70 SNP rs415895 Exon Normal Normal B*40:01 (53)
LB-TRIP10-1EPC G[e/G][P/S]QDL[C/G]TL TRIP10 SNP rs1049229 3′ UTR Normal Alternative B*40:01 (53)
rs1049230
rs1049232
SLC1A5 AE[A/P]TANGGLAL SLC1A5 SNP rs3027956 Exon Normal Normal B*40:02 (39)
HB-1H EEKRGSL[H/Y]VW HMHB1 SNP rs161557 Exon Normal Normal B*44:03 (54)
HB-1Y EEKRGSL[H/Y]VW HMHB1 SNP rs161557 Exon Normal Normal B*44:03 (55)
UGT2B17/B44 AELLNIPFLY UGT2B17 Gene deletion Polymorphic Polymorphic B44 (44)
ACC-2 KEFED[D/G]IINW BCL2A1 SNP rs3826007 Exon Normal Normal B*44:03 (42)
ACC-6 MEIFIEVFSHF HMSD SNP rs9945924 Intron Polymorphic Polymorphic B*44:03 (56)
DPH1 S[v/L]LPEVDVW DPH1 SNP rs35394823 Exon Normal Normal B*57:01 (45)
HLA-ii MiHA MiHA/Ava Gene variant rs number Location Transcriptb Proteinb HLA Reference
LB-MTHFD1-1Q SSIIAD[Q/R]IALKL MTHFD1 SNP rs2236225 Exon Normal Normal DRB1*03:01 (26)
LB-LY75-1K LGITYR[n/K]KSLMWF LY75 SNP rs12692566 Exon Normal Normal DRB1*13:01 (26)
SLC19A1 [R/H]LVCYLCFY SLC19A1 SNP rs1051266 Exon Normal Normal DRB1*15:01 (57)
LB-PTK2B-1T VYMND[T/K]SPLTPEK PTK2B SNP rs751019 Exon Normal Normal DRB3*01:01 (26)
LB-MR1-1R YFRLGVSDPI[R/H]G MR1 SNP rs2236410 Exon Normal Normal DRB3*02:02 (26)
CD19 WEGEPPC[L/V]P CD19 SNP rs2904880 Exon Normal Normal DQB1*02:01 (58)
LB-PI4K2B-1S SRSS[S/P]AELDRSR PI4K2B SNP rs313549 Exon Normal Normal DQB1*06:03 (59)
UTDP4-1 R[i/N]LAHFFCGW ZDHHC12 SNP rs11539209 Exon Normal Normal DPB1*04 (60)
aThe polymorphic amino acid in the epitope is indicated between brackets (MiHA/AV = allelic variant).
bNormal and alternative transcripts and proteins are expressed independently of the SNP in both patient and donor, whereas polymorphic transcripts and proteins are de novo 
created by the SNP and, thus, restricted to the patient.
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Whereas T-cells are used to identify MiHA by forward 
strategies; in reverse strategies, peptides are selected to search 
for specific T-cells. Polymorphic peptides identified in HLA-
ligandomes (38, 51), hematopoiesis-restricted genes (52, 55, 61), 
and peptides identified based on association of SNPs with good 
clinical outcome after alloSCT (36) have been selected to search 
for specific T-cells in transplanted patients or healthy individuals.
In total, 48 HLA class I-restricted and 8 HLA class 
II-restricted autosomal MiHA have thus far been character-
ized. These numbers are expected to rapidly increase in the 
near future, in particular, if WGAs is performed with cell 
panels for which all SNPs are measured by whole genome 
sequencing.
MOLeCULAR MeCHAniSMS
HLA class I-restricted autosomal MiHA are generated by different 
molecular mechanisms. An overview of the various mechanisms 
by which genetic variants create MiHA is shown in Figure 1. Of 
the 48 HLA class I-restricted MiHA, 36 antigens are encoded by 
SNPs in coding exons, leading to single amino acid changes in 
proteins that are translated from primary gene transcripts in the 
normal reading frame (Figure 1A). MiHA can, however, also be 
translated from normal gene transcripts in an alternative reading 
frame. These SNPs can be located in coding exons (C19ORF48, 
LB-ECGF1-1H, LB-ADIR-1F, LB-ARHGDIB-1R) (Figure  1B) 
or in 5’ or 3’ UTR regions (LB-TRIP10-1EPC) (Figure  1C). 
Though not yet discovered, it is expected that MiHA can also be 
encoded by SNP in intron regions that are retained in alterna-
tive transcripts (Figure  1D). Proteins translated in alternative 
reading frames are considered as aberrant proteins that lack any 
cellular function, the so-called defective ribosomal products 
(DRiPs). DRiPs are rapidly degraded during or shortly after 
translation and evidence has been found that they may be a main 
source of peptide precursors for T-cell immunosurveillance 
(62). Degradation is an important factor for HLA presentation 
(63), but relative abundance of normal functional proteins in 
the cell may counteract the actual contribution of DRiPs to the 
HLA-ligandome.
In addition to the proteins described above that are expressed 
independently of the SNP in both patient and donor, MiHA 
can also be derived from proteins or protein products that are 
de novo created by SNPs. Expression of these polymorphic 
proteins is restricted to the patient and allelic variants in the 
donor do not exist. As a result, the epitope that is recognized 
by the T-cell can be derived from another protein region than 
the amino acids that are directly encoded by the SNP. Examples 
of antigens from polymorphic proteins that are de novo cre-
ated are LRH-1, an antigen that is produced by an insertion/
deletion variant (INDEL) that induces a frameshift in protein 
translation (Figure 1E) and PANE1, which is an antigen from an 
elongated protein created by a SNP that disrupts the stop codon 
(Figure 1F). PANE1 and LRH-1 are both polymorphic proteins 
translated from transcripts that are expressed independently of 
the SNP in both patient and donor. However, MiHA can also 
be encoded by transcripts that are newly created by the SNP. 
These polymorphic transcripts are expressed in the patient and 
do not exist in the donor. Antigens encoded by polymorphic 
transcripts that are newly created by SNPs are ZAPHIR, 
which is translated from a ZNF419 transcript in which an 
intron is retained (Figure 1G), and ACC-6, which is encoded 
by an HMSD transcript that is generated by exon skipping 
(Figure  1H). Finally, MiHA can be encoded by polymorphic 
genes as illustrated by UGT2B17, which is present in the patient 
but absent in the donor genome (Figure 1I).
The numbers of MiHA that have been characterized for each 
molecular mechanism as shown in Figure  1 probably do not 
reflect the actual contribution of the various mechanisms to the 
entire repertoire of MiHA that are recognized by specific T-cells 
after alloSCT. This is suggested by the finding that for various 
T-cell clones, associating SNPs have successfully been identified 
by WGAs in genomic regions outside known exons, whereas 
epitope discovery failed due to absence of SNP disparities in 
the normal gene transcript. MiHA recognized by these T-cells 
are probably encoded by cryptic transcripts. RNA-sequence 
data can be used to search for these cryptic transcripts in the 
genomic region that contains the associating SNPs and single 
RNA-sequence reads can be analyzed to determine the exact 
sequence composition of the transcripts, thereby facilitating 
discovery of these MiHA. As such, implementation of RNA-
sequence analysis in a combined approach of whole genome 
and transcriptome analysis may increase the efficiency of MiHA 
discovery. The various molecular mechanisms how genetic vari-
ants create MiHA as shown in Figure 1 are probably similar for 
neoantigens. Neoantigens are peptides created by tumor-specific 
mutations that are presented by HLA and recognized by specific 
T-cells (64). In cancer neoantigen discovery, research is focused 
on selecting peptides encoded by mutations in coding exons 
with single amino acid changes in the normal protein reading 
frame (Figure  1A), whereas other molecular mechanisms 
(Figures  1B–H) are often not taken into consideration. RNA-
sequence analysis may, therefore, also be relevant to elucidate 
transcript variants for neoantigens in particular since splicing 
defects often occur in cancer (65).
TiSSUe DiSTRiBUTiOn
The tissue distribution of MiHA is an important factor in clini-
cal manifestations caused by immune responses after alloSCT. 
Various T-cells recognize leukemic cells in vitro with no or mini-
mal reactivity against non-hematopoietic cells. These T-cells are 
expected to mediate beneficial GvL after alloSCT without GvHD. 
Other T-cells are reactive with both hematopoietic and non-
hematopoietic cells, suggesting a role in GvHD. Since in alloSCT, 
patient hematopoiesis is replaced by a blood-forming system 
from a healthy donor, donor T-cells for hematopoiesis-restricted 
MiHA eliminate the malignant cells of the patient, while sparing 
healthy hematopoietic cells of donor origin. Therefore, discovery 
of hematopoietic MiHA is an explicit research goal.
Various methods are available to investigate the tissue distri-
bution of MiHA to estimate their efficacy and toxicity as T-cell 
targets. Toxicity can be analyzed by measuring T-cell reactivity 
against non-hematopoietic cells from organs that are targeted in 
GvHD. This analysis, however, requires collection of a variety of 
FiGURe 1 | Molecular mechanisms by which genetic variants create autosomal MiHA. Normal non-polymorphic sequences are indicated in gray, whereas 
alternative non-polymorphic sequences are shown in black. Polymorphic patient-specific sequences are shown in red and donor-specific sequences are indicated in 
green (if allelic variants exist). Whether the allelic variants are actually presented on the cell surface is also dependent on intracellular processing and presentation 
mechanisms, which are not taken into consideration in this figure. (A) MiHA created by SNPs in primary gene transcripts in the normal reading frame. (B) MiHA 
created by SNPs in primary gene transcripts in an alternative reading frame. (C) MiHA created by SNPs in 5´ or 3´ UTR of primary gene transcripts.  
(D) MiHA created by intron SNPs as retained in alternative gene transcripts. (e) MiHA derived from polymorphic proteins as created by frameshift insertions or 
deletions in primary gene transcripts. (F) MiHA derived from polymorphic proteins as created by SNP in alternative gene transcripts. (G) MiHA translated from intron 
sequences in polymorphic gene transcripts as created by exon or intron SNPs. (H) MiHA translated from polymorphic gene transcripts in which exon sequences are 
skipped as created by exon or intron SNPs. (i) MiHA encoded by polymorphic genes.
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tissues expressing the relevant MiHA and HLA restriction allele. 
Skin fibroblasts are frequently used to estimate toxicity and have 
also been cultured with cytokines to mimic the inflammatory 
environment of the early post-transplantation period. T-cells 
often recognize skin fibroblasts when cultured under inflam-
matory conditions, what may be explained by efficient antigen 
processing and presentation and enhanced surface expression 
of HLA, costimulatory, and adhesion molecules. Other non-
hematopoietic cells, however, are more difficult to culture 
and often not available in quantities that allow in depth T-cell 
analysis. Therefore, as second best option, the tissue distribution 
can be investigated by gene expression analysis. Thus far, only a 
limited number of MiHA are encoded by genes with restricted or 
predominant expression in (malignant) hematopoietic cells, i.e., 
HMHB1 (54), MYO1G (66), HMHA1 (67), BCL2A1 (42), P2×5 
(47), CENPM (40), HMSD (56), KIAA1551 (37), and ARHGDIB 
(68). Although gene expression analysis allows rapid selection 
of hematopoietic antigens, the therapeutic value of MiHA needs 
to be validated by demonstrating the capacity of specific T-cells 
to kill leukemic cells and confirming their failure to react with 
non-hematopoietic cells.
IN VIVO iMMUne ReSPOnSeS
Minor histocompatibility antigens characterization enabled ex 
vivo quantification of specific T-cells by pMHC multimers in 
individual patients after alloSCT. Staining with pMHC multimers 
demonstrated a peak in the immune response in patients who 
responded to DLI after HLA-matched alloSCT (27, 37, 47, 69). In 
these patients, high frequencies of circulating T-cells coincided 
with development of GvL. Detailed analysis of peak responses 
between 4 and 12 weeks after DLI demonstrated that a diversity 
of HLA class I- and II-restricted MiHA are targeted by CD8 and 
CD4 T-cells (26, 27, 53). These T-cells expand and retract with 
similar kinetics, although frequencies and timing of the peak may 
differ between MiHA (27, 53).
Although GvL after alloSCT is often accompanied with 
GvHD, strong anti-tumor responses without severe side effects 
are occasionally observed (69), illustrating that GvL can be sepa-
rated from GvHD. In the pathophysiology of GvHD, the tissue 
distribution of MiHA is important as well as the frequencies of 
circulating T-cells, their homing behavior and capacity to destroy 
non-hematopoietic cells in situ (70). Although tissue distribution 
is relevant, occurrence of GvHD cannot entirely be explained 
by induction of T-cells targeting MiHA on non-hematopoietic 
tissues. This became clear when T-cells for hematopoietic and 
ubiquitous MiHA were simultaneously detected in patients 
with severe GvHD (71) and patients without GvHD (53). Since 
immune responses in patients with GvHD are generally strong, it 
can be speculated that T-cell reactivity against non-hematopoietic 
tissues needs to exceed a certain threshold in GvHD (72). Since 
T-cells for ubiquitous MiHA may stimulate development of GvL 
by releasing cytokines, strategies that retain reactivity against 
healthy tissues below the threshold may effectively separate GvL 
from GvHD.
THeRAPeUTiC USe
As the number of characterized MiHA increases, T-cells from 
different patients more often recognize MiHA that are already 
known, suggesting that the repertoire of MiHA that are presented 
by HLA and recognized by specific T-cells is limited and follow 
rules for immunodominance that cannot be predicted by measur-
ing only SNP disparities (73). If true, a large proportion of all 
MiHA with balanced population frequencies will be character-
ized in the coming years. Discovery of these MiHA is needed to 
analyze and compare in vivo immune responses in GvL and GvHD 
with respect to specificity, diversity, frequency, and dynamics of 
specific T-cells. Moreover, it enables to follow GvL and GvHD in 
large patient groups, which is essential to investigate and compare 
efficacy and toxicity of different alloSCT (and DLI) transplanta-
tion protocols.
With the discovery of a large proportion of common MiHA, 
a variety of targets become available for therapy to augment GvL 
after alloSCT (74, 75). One strategy is in  vitro production and 
adoptive transfer of donor T-cells for hematopoietic MiHA (75, 
76). Patients with leukemia who relapsed after alloSCT have been 
treated with in vitro expanded T-cells for leukemic cells (77, 78), 
T-cells for HA-1 (79) or MiHA-specific T-cells that lacked reactiv-
ity against fibroblasts (45). Other strategies for adoptive transfer 
are isolation of MiHA-specific T-cells from the DLI by pMHC 
multimers and T-cell receptor (TCR) gene transfer. In the latter 
study, patients are treated with virus-specific donor T-cells that 
are genetically engineered with the TCR for HA-1 (80). Besides 
adoptive transfer, patients with hematological malignancies can 
be in vivo vaccinated with donor (or patient) dendritic cells loaded 
with peptides or mRNA (81–83). In conclusion, hematopoietic 
MiHA (and their specific TCRs) may be easily implemented in 
ongoing clinical trials to increase efficacy, reduce toxicity, and 
broaden applicability of immunotherapy after alloSCT.
COnCLUDinG ReMARKS
In this review, the various molecular mechanisms how genetic 
variants create autosomal MiHA are described as well as the 
relevance of these antigens as tools to understand the biology 
of GvL and GvHD and as targets for immunotherapy to treat 
hematological cancers after alloSCT. Although more MiHA are 
needed for comprehensive understanding and manipulation by 
immunotherapy, this review shows insight into the composi-
tion and kinetics of in  vivo immune responses with respect to 
specificity, diversity, and frequency of specific T-cells and surface 
expression of HLA-peptide complexes and other (accessory) 
molecules on the target cell. A complex interplay between these 
factors and their environment (84) ultimately determines the 
spectrum of clinical manifestations that are caused by immune 
responses after alloSCT.
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